Wire · opportunities
COPD trial wins spur broad respiratory hopes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
AstraZeneca's IL-33-targeted antibody tozorakimab has shown a 30% reduction in COPD exacerbations across all blood eosinophil counts, addressing a major treatment gap. The company has filed for FDA approval, expecting a decision in early 2027, and this success could trigger broader development of IL-33-targeted therapies in respiratory diseases.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your respiratory biotech project can now target a proven market gap in COPD beyond eosinophilic patients. Tozorakimab's pending US approval opens a path to compete in biologics that treat hard-to-control lung inflammation.
◆ Coverage
1 source · 5 Oct 2026
◆ Related on Wire
◆ Topics